Katkin Keith
SEC-identified person · CIK 1314596 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Emergent Biosolutions Inc. EBS | Director | filed 2022 - 2026 |
| Syndax Pharmaceuticals Inc SNDX | Director | filed 2017 - 2026 |
| Tokai Pharmaceuticals Inc TKAI | Director | filed 2017 - 2026 |
| Rigel Pharmaceuticals INC RIGL | Director | filed 2015 - 2021 |
| Urovant Sciences Ltd. UROV | Director · PEO;CEO/Urovant Sciences, Inc. | filed 2018 - 2020 |
| Kalvista Pharmaceuticals, Inc. KALV | Director | filed 2015 - 2015 |
| Avanir Pharmaceuticals, INC. AVNR | Director · Sr. V.P. of Sales & Marketing | filed 2006 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.